McKesson Specialty Health oncology and complex care pharmacy services company has been finalized by the Janssen Pharmaceutical Companies of Johnson & Johnson which is considered the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer (NM-CRPC).
ERLEADA is a next-generation androgen receptor inhibitor for the treatment of patients with NM-CRPC with the goal of delaying metastases. Approval is based on an FDA Priority Review of Phase 3 SPARTAN clinical trial data,which showed that ERLEADA decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years in patients with NM-CRPC. The major efficacy outcome was supported by statistically significant improvements for secondary endpoints, including time to metastasis, progression-free survival, and time to symptomatic progression. The study was published in the New England Journal of Medicine.
Brandon Tom, vice president, Biopharma Services, McKesson Specialty Health said “We’re delivering this important new drug to patients living with prostate cancer, and physicians nationwide now have an important and much-needed treatment option that has been shown to delay the progression of castration-resistant prostate cancer.”